Precision Prostate Cancer Pathway Brochure form
Precision Prostate Cancer Pathway Brochure Please fill out the form below to download the brochure.
mdxhealth.comCrawled Nov 20, 2026
Precision Prostate Cancer Pathway Brochure Please fill out the form below to download the brochure.
The GPS Patient Report Interpretation Guide references NCCN Clinical Practice Guidelines and studies published in *Eur Urol* and *Urology*.
The Precision Prostate Cancer Pathway integrates three biomarker tests to support clinical decision-making for prostate cancer.
mdxhealth offers four precision diagnostic assays for personalized urologic patient care.
Mdxhealth Test Menu Brochure Please fill out the form below to download the brochure.
The Confirm mdx test analyzes DNA methylation markers to detect prostate cancer in unsampled tissue after a negative biopsy.
A 2013 study in *BMC Genomics* validated the Oncotype DX prostate cancer assay for use with prostate needle biopsies.
A patient with intermediate-risk prostate cancer used the Genomic Prostate Score test to inform treatment decisions.
mdxhealth develops and validates molecular diagnostic assays for prostate cancer using its proprietary gene portfolio.
mdxhealth provides molecular diagnostic tests for urologic cancers, using genetic and epigenetic technologies to guide treatment decisions. Its headquarters are in Herstal, Belgium, and Nijmegen, Netherlands, with U.S. operations.
mdxhealth publishes annual financial reports under IFRS, with its fiscal year ending December 31.
mdxhealth seeks partnerships to advance precision diagnostics through collaboration in clinical care, research, and biotechnology.
mdxhealth provides molecular diagnostic solutions for detecting aggressive prostate cancer and urologic diseases.